News Contact Us

Ofatumumab shows better efficacy versus Teriflunomide in RMS studies

Author : Pankaj Singh | Published Date : 2019-08-31 
  • Head to head Phase III ASCLEPIOS studies I & II of OMB157 (ofatumumab) have revealed considerable superiority in reducing the ARR (annualized relapsed rate) in patients suffering from RMS (relapsing forms of multiple sclerosis) in comparison with terinuflomide.
  • OMB157 also met the secondary key endpoints of delaying time to confirmed progression of disability.
  • Ofatumumab safety profile was in keeping with the Phase II results, delivering sustained effectiveness.

Danish biotechnology expert Genmab A/S has reportedly announced Novartis’ positive results for OMB157 (ofatumumab) observed from the ASCLEPIOS I & II studies in Phase III. The studies, conducted to test the effectiveness and safety of monthly ofatumumab 20g (administered subcutaneously) vs once-daily teriflunomide 14g (administered orally) in adult patients with relapsing multiple sclerosis forms (RMS), showed that both treatments met primary endpoints, with ofatumumab showing profound and clinically significant reduction in confirmed relapse numbers, assessed as the ARR.

Key secondary endpoints for delay in time to confirm disability progression were met as well.

According to Genmab CEO, Jan van de Winkel, PhD, the information gathered through these studies indicates a potential turning point for ofatumumab and reinforces the belief that, if approved, it could become the 1st subcutaneously administered B-cell therapy for RMS, which patients can self-administer. He further expressed Genmab’s anticipation for the authorities’ feedback and delight for this new stage in the development of ofatumumab.

Novartis, that carries the right to develop and market of atumumab licensed by Genmab, has started plans to begin submissions to health authorities by the end of the year, on the basis of data collected during the ASCLEPIOS studies.

Phase III ASCLEPIOS I & II study results will be presented on the 13th of September in a late-breaker presentation format, at the esteemed 35th Congress of the ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis). The event is expected to take place from 11th to 13th September 2019, in Stockholm.

Source Credit: https://www.globenewswire.com/news-release/2019/08/30/1908824/0/en/Ofatumumab-Demonstrates-Superiority-Versus-Teriflunomide-in-Two-Head-to-Head-Phase-III-Multiple-Sclerosis-Studies.html


About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Cipla launches generic version of Remdesivir at a price of ₹4,000

Published Date: 2020-07-10         Author: Pankaj Singh

Cipla Limited, the multinational pharmaceutical company, has reportedly launched a generic version of the remdesivir drug (Cipremi) at a price of ?4,000 per 100 mg vial, making it among the least priced COVID-19 treatment available across the globe. According to sources familiar with the knowledg... Read More

Revival in UK hotel bookings after COVID-19 downturn, says Premier Inn

Published Date: 2020-07-09         Author: Pankaj Singh

UK has registered a revival in hotel bookings for conventional regional tourist destinations as people have started planning summer trips to the seaside and countryside, stated Premier Inn owner. The Chief Executive of Whitbread, Alison Brittain, has stated that larger cities like London continue... Read More

Fujitsu gravitates toward 'new normal' with new office working style

Published Date: 2020-07-08         Author: Pankaj Singh

Fujitsu Limited, a Japanese multinational IT company headquartered in Tokyo, has reportedly announced that it will boost its shift to becoming a digital transformation organization with an ambitious plan to transform the working style for its employees in Japan in the light of COVID-19 pandemic. ... Read More

© 2020 Fractovia. All Rights Reserved